News coverage about OvaScience (NASDAQ:OVAS) has trended somewhat positive recently, Accern reports. Accern scores the sentiment of media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. OvaScience earned a media sentiment score of 0.05 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 44.0225544726119 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

These are some of the news stories that may have impacted Accern Sentiment’s scoring:

OVAS has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target on shares of OvaScience in a report on Monday, November 6th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $1.50 price target on the stock in a report on Wednesday, October 4th.

Shares of OvaScience (NASDAQ OVAS) traded up $0.06 during midday trading on Wednesday, hitting $1.43. The stock had a trading volume of 801,800 shares, compared to its average volume of 576,513. OvaScience has a 12-month low of $1.25 and a 12-month high of $3.10.

TRADEMARK VIOLATION WARNING: This article was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international trademark and copyright laws. The correct version of this article can be accessed at https://www.watchlistnews.com/ovascience-ovas-receiving-somewhat-favorable-news-coverage-analysis-shows/1774795.html.

About OvaScience

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Insider Buying and Selling by Quarter for OvaScience (NASDAQ:OVAS)

Receive News & Ratings for OvaScience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OvaScience and related companies with MarketBeat.com's FREE daily email newsletter.